A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Enrique Alvarez, MD, PhD
Study ID
Protocol Number: 21-4825
More information available at ClinicalTrials.gov: NCT05147220
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers